– SWITZERLAND, Lugano – Gain Therapeutics, Inc. today announced the addition of Dr. Dov Goldstein, Gwen Melincoff, Dr. Claude Nicaise, and Hans Peter Hasler to its Board as independent Directors.
The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding.
“We are pleased to welcome such a distinguished group of board members at this pivotal time for Gain,” said CEO, Eric Richman. “Their decades of experience across the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and determine how our proprietary Site-Directed Enzyme Enhancement Therapy computational platform technology can best be leveraged to help patients in need of new treatment options. I look forward to working with Dr. Goldstein, Ms. Melincoff, Dr. Nicaise and Mr. Hasler.”
Concurrent with the Board additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board.
Dr. Khalid Islam, Board Chairman added, “I would like to thank Dr. Lorenzo Leoni and Dr. Marianne Bjordal for their important contributions and guidance during the last several years. With the addition of Dr. Goldstein, Ms. Melincoff, Dr. Nicaise, and Mr. Hasler to our board, Gain is ideally positioned to build upon the considerable growth we’ve achieved over the past year. I am confident that these new directors will provide valuable insights and perspectives given their track records in research, clinical, regulatory, and commercial. I look forward to their engagement and assistance in guiding our strategies and objectives to advance our pipeline of innovative and breakthrough therapies as Gain therapeutics continues its ongoing evolution.”
Dr. Dov Goldstein
Dr. Goldstein brings more than two decades of experience in the biotech industry to the Gain board of directors. He is currently the CFO and Chief Business Officer of Indapta Therapeutics, a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers and serves on the board of NeuBase Therapeutics. Before Indapta, Dr. Goldstein served as CEO at RIGImmune. From 2006-2019, he worked at Aisling Capital, a private investment firm. Dr. Goldstein also served as the CFO of Loxo Oncology, Inc. and Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005.
Dr. Goldstein has served as a director at ADMA Biologics, Inc., Esperion Therapeutics, Inc., and Cempra, Inc. (which was acquired by Melinta Therapeutics, Inc.).
Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School, and an M.D. from Yale School of Medicine. He completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital.
About Gwen Melincoff
Ms. Melincoff is a seasoned business development and venture professional with over 25 years of deal-making and management experience in the biotechnology and pharmaceutical industries. Ms. Melincoff is currently managing director at Gemini Advisors LLC, a biopharmaceutical consultancy, and an advisor to Verge Genomics, a startup drug discovery company, and Agent Capital. Previously, Ms. Melincoff served as VP, Business Development at BTG International Inc., a UK-specialist healthcare company. Before BTG, Ms. Melincoff was SVP, Corporate Development at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms. Melincoff was VP, Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten years in a number of their health care companies.
She serves on the board of directors of several biopharmaceutical companies, including Protalix Biotherapeutics, Inc., Collegium Pharmaceutical, Inc., and Soleno Therapeutics, Inc. and has previously served on the boards of Photocure ASA, Kamada Ltd., and Tobira Therapeutics Inc.
Ms. Melincoff holds a B.S. in Biology from George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University.
About Dr. Claude Nicaise
Dr. Nicaise is the founder of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies. Dr. Nicaise serves on the board for Sarepta Therapeutics, Inc., chairs their Compensation committee, and is a member of their Research and Development committee. Since 2015, Dr. Nicaise has served as an EVP, Regulatory at Ovid Therapeutics Inc., a company that develops medicines for orphan diseases of the brain. Dr. Nicaise was SVP, Strategic Development, and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as VP, Global Development, VP, Worldwide Regulatory Science and Strategy, and leadership positions in Oncology, Infectious Disease, and Neuroscience development.
Dr. Nicaise received his medical degree from the Université Libre de Bruxelles in Belgium.
About Hans Peter Hasler
Mr. Hasler was the CEO of Vicarius Pharma AG, a privately held European Bio-Pharma company until 2020. He also is a Senior Advisor of SBTech Global Advisory. His prior experiences include Elan Corporation, Dublin, where he was COO, and Biogen Inc., Boston, where his positions included COO, and EVP, Head of Global Neurology and International. Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as SVP, Chief Marketing Officer, and Managing Director of Wyeth Group Germany, Münster.
Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland, Chairman of the Board of Shield Therapeutics, London, and a Director of Minerva Neurosciences in Boston (Nasdaq).
He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.
About Gain Therapeutics, Inc.
Gain Therapeutics is redefining drug discovery with its See-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3G Future Health Fund (previously known as Helsinn Investment Fund), and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly-owned subsidiary of Gain Therapeutics, Inc.
For more information: https://www.gaintherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.